COSCIENS Biopharma Inc.
CSCI.TO
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 30.04% | 36.12% | -46.84% | -20.74% | 3.42% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 30.04% | 36.12% | -46.84% | -20.74% | 3.42% |
| Cost of Revenue | -15.50% | 7.56% | -9.11% | 2.63% | 9.62% |
| Gross Profit | 130.68% | 114.91% | -70.28% | -43.05% | -8.06% |
| SG&A Expenses | -46.35% | -46.78% | 279.63% | -29.78% | -27.56% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -36.74% | -35.29% | 45.70% | -46.82% | -29.40% |
| Operating Income | 122.40% | 72.55% | -607.01% | 56.91% | 49.83% |
| Income Before Tax | 91.11% | 93.16% | 61.53% | 69.00% | -19.83% |
| Income Tax Expenses | -- | -- | -99.08% | -- | 100.42% |
| Earnings from Continuing Operations | 91.12% | 93.16% | 67.57% | 68.39% | -59.92% |
| Earnings from Discontinued Operations | -- | 1,215.19% | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 92.52% | 394.31% | 67.57% | 68.39% | -89.94% |
| EBIT | 122.40% | 72.55% | -607.01% | 56.91% | 49.83% |
| EBITDA | 147.53% | 83.33% | -957.69% | 58.76% | 52.72% |
| EPS Basic | 92.49% | 394.66% | 68.00% | 69.10% | -33.63% |
| Normalized Basic EPS | 91.07% | 93.15% | -274.29% | 64.98% | 15.69% |
| EPS Diluted | 92.49% | 394.51% | 68.00% | 69.10% | -33.63% |
| Normalized Diluted EPS | 91.07% | 93.15% | -274.29% | 64.98% | 15.69% |
| Average Basic Shares Outstanding | -0.45% | -0.11% | 1.36% | 2.28% | 42.13% |
| Average Diluted Shares Outstanding | -0.45% | -0.11% | 1.36% | 2.28% | 42.13% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |